• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Meridian Bioscience Inc. (Amendment)

    11/2/22 7:48:15 PM ET
    $VIVO
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $VIVO alert in real time by email
    SC 13D/A 1 brhc10043657_sc13da.htm SC 13D/A
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D. C. 20549
     
    SCHEDULE 13D
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. 1)*

     Meridian Bioscience, Inc.

    (Name of Issuer)

    Common Stock, no par value


    (Title of Class of Securities)

    589584101

    (CUSIP Number of Class of Securities)

    David J. Snyderman
    Magnetar Capital LLC
    1603 Orrington Ave.
    Evanston, Illinois 60201
    (847) 905-4400


    (Name, Address and Telephone Number of Person Authorized
    to Receive Notices and Communications)

    October 24, 2022

    (Date of Event which Requires Filing of this Statement)

    If the filing person has previously filed a Statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D and is filing this Schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ☐
     
    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 240.13d-7(b) for other parties to whom copies are to be sent.
     
    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
     
    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


    CUSIP No. 91734M103
    SCHEDULE 13D
    Page 2 of 11

    1
    NAMES OF REPORTING PERSONS
     
     
    Magnetar Financial LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    2,260,688
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    2,260,688
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    2,260,688
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    5.17%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IA; OO
     
     
     
     


    CUSIP No. 91734M103
    SCHEDULE 13D
    Page 3 of 11

    1
    NAMES OF REPORTING PERSONS
     
     
    Magnetar Capital Partners LP
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    2,260,688
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    2,260,688
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    2,260,688
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    5.17%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    HC; OO
     
     
     
     


    CUSIP No. 91734M103
    SCHEDULE 13D
    Page 4 of 11

    1
    NAMES OF REPORTING PERSONS
     
     
    Supernova Management LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    2,260,688
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    2,260,688
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    2,260,688
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    5.17%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    HC; OO
     
     
     
     


    CUSIP No. 91734M103
    SCHEDULE 13D
    Page 5 of 11

    1
    NAMES OF REPORTING PERSONS
     
     
    David J. Snyderman
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States of America
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    2,260,688
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    2,260,688
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    2,260,688
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    5.17%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    HC; IN
     
     
     
     


    SCHEDULE 13D
     
    This Amendment No. 1 (the “Amendment No. 1”) relates to the Statement of Beneficial Ownership on Schedule 13D filed jointly by Magnetar Financial LLC, a Delaware limited liability company (“Magnetar Financial”), Magnetar Capital Partners LP, a Delaware limited partnership (“Magnetar Capital Partners”), Supernova Management LLC, a Delaware limited liability company (“Supernova Management”), and Alec N. Litowitz (“Mr. Litowitz”) with the SEC on September 19, 2022, (as amended by this Amendment No. 1, the “Schedule 13D”).  This Amendment No. 1 is being filed to remove Mr. Litowitz as a Reporting Person and replace him with David J. Snyderman who, effective October 24, 2022, replaced Mr. Litowitz as the Chief Executive Officer of Magnetar Financial and the Manager of Supernova Management.

    Except as set forth below, all Items of the Schedule 13D remain unchanged. All capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13D.

    ITEM 2.
    IDENTITY AND BACKGROUND
     
    Item 2 of the Schedule 13D is hereby amended and restated in its entirety as follows:
     
    (a)          The persons filing this Statement are Magnetar Financial LLC, a Delaware limited liability company (“Magnetar Financial”), Magnetar Capital Partners LP, a Delaware limited partnership (“Magnetar Capital Partners”), Supernova Management LLC, a Delaware limited liability company (“Supernova Management”), and David J. Snyderman (“Mr. Snyderman”) (collectively, the “Reporting Persons”).
     
    This Statement relates to Shares held for the accounts of each of (i)  Magnetar PRA Master Fund Ltd, a Cayman Islands exempted company (“PRA Master Fund”), (ii), Magnetar Systematic Multi-Strategy Master Fund Ltd, a Cayman Islands exempted company, (“Systematic Master Fund”), and one Managed Account for the clients of Magnetar Financial (the “Managed Account”) (collectively the “Funds”).
     
    Magnetar Financial is a Securities and Exchange Commission (“SEC”) registered investment adviser under Section 203 of the Investment Advisers Act of 1940, as amended, and manager of investment funds and managed accounts. Magnetar Financial serves as investment adviser to each of the Funds. In such capacity, Magnetar Financial exercises voting and investment power over the Shares held for the accounts of each of the Funds.  Magnetar Capital Partners serves as the sole member and parent holding company of Magnetar Financial. Supernova Management is the general partner of Magnetar Capital Partners. The Manager of Supernova Management is Mr. Snyderman.
     
    (b)          The business address of each of the Reporting Persons is 1603 Orrington Avenue, 13th Floor, Evanston, Illinois 60201.
     
    (c)          Each of the Funds is a private investment fund; Magnetar Financial is a privately-held SEC registered investment adviser and manager of investment funds and managed accounts; Magnetar Capital Partners is a privately-held limited partnership and serves as the sole member and parent holding company of Magnetar Financial; Supernova Management is a privately-held limited liability company and is the general partner of Magnetar Capital Partners; and Mr. Snyderman is a citizen of the United States of America, Manager of Supernova Management and Chief Executive Officer of Magnetar Financial.


    (d)          None of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
     
    (e)          None of the Reporting Persons has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which such Reporting Person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
     
    (f)          Magnetar Financial is a Delaware limited liability company. Magnetar Capital Partners is a Delaware limited partnership. Supernova Management is a Delaware limited liability company. Mr. Snyderman is a citizen of the United States of America.
     
    ITEM 3.
    SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
     
    Item 3 of the Schedule 13D is hereby amended and restated in its entirety as follows:
     
    The aggregate amount of funds used by the one of the Reporting Persons in purchasing the  2,260,688 Shares reported herein on behalf of the Funds have come directly from the assets of the Fund, which may at any given time, have included margin loans made by brokerage firms in the ordinary course of business. The aggregate amount of funds used by the Reporting Person in purchasing the Shares on behalf of the Funds was $74,864,174.99 (excluding commissions and other execution-related costs).

    ITEM 4.
    PURPOSE OF TRANSACTION

    Item 4 of the Schedule 13D is hereby amended to add the following information for updating:

    Since the filing of the Schedule 13D with the SEC on September 19, 2022, the Reporting Persons sold 3,336 Shares between September 30, 2022 and October 7, 2022 reported herein which consists of 3,336 Shares sold for the benefit of the Managed Account.

    Since the filing of the Schedule 13D with the SEC on September 19, 2022, the Reporting Persons purchased 15,699 Shares on November 1, 2022 reported herein which consists of 8,294 Shares purchased for the benefit PRA Master Fund and 7,405 Shares purchased for the benefit of the Systematic Master Fund.


    ITEM 5.
    INTEREST IN SECURITIES OF THE ISSUER
     
    Item 5(a)-(c) of the Schedule 13D is hereby amended to add the following information for updating:
     
    The Company reported in their Form 10-Q filed on August 5, 2022 that 43,747,969 Shares were issued and outstanding as of July 31, 2022.
     
    (a)          As of the close of business November 1, 2022, each of the Reporting Persons may have been deemed to have beneficial ownership of 2,260,688 Shares, which consisted of (i) 1,944,794 Shares held for the benefit of PRA Master Fund, (ii) 310,465 Shares held for the benefit of Systematic Master Fund, and (iii) 5,429 Shares held for the benefit of the Managed Account and all such Shares represented beneficial ownership of approximately 5.17% of the Shares.

    (b)          As of the close of business November 1, 2022, each of the Reporting Persons may have been deemed to share the power to vote and direct the disposition of 2,260,688 Shares, which consisted of (i) 1,944,794 Shares held for the benefit of PRA Master Fund, (ii) 310,465 Shares held for the benefit of Systematic Master Fund, and (iii) 5,429 Shares held for the benefit of the Managed Account and all such Shares represented beneficial ownership of approximately 5.17% of the Shares.

    (c)          Except as set forth on Schedule B attached hereto, the Funds had no transactions in the Shares during the 60 days preceding the date of filing of this Statement. All of the transactions set forth on Schedule B attached hereto were effected in the ordinary course of business of Magnetar Financial for the accounts of each of the Funds. The transactions in the Shares set forth on Schedule B were effected in open market transactions on the NASDAQ and various other trading markets.
     
    ITEM 6.
    CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO THE SECURITIES OF THE ISSUER
     
    Item 6 of the Schedule 13D is hereby amended to add the following information for updating:
     
    Pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the Reporting Persons have entered into an agreement with respect to the joint filing of this Statement, and any amendment or amendments hereto.

    ITEM 7.
    MATERIAL TO BE FILED AS EXHIBITS

    Exhibit No.
    Description
       
    99.2
    Joint Filing Agreement, dated as of November 2, 2022 among the Reporting Persons.


    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    Dated: November 2, 2022
           
             
     
    MAGNETAR FINANCIAL LLC
     
             
     
    By:
    Magnetar Capital Partners LP, its Sole Member
             
     
    By:
    /s/ David J. Snyderman
     
       
    Name:
    David J. Snyderman

       
    Title:
    Manager of Supernova Management LLC, the General Partner of Magnetar Capital Partners LP
             
     
    MAGNETAR CAPITAL PARTNERS LP
     
             
     
    By:
    /s/ David J. Snyderman
     
       
    Name:
    David J. Snyderman
     
       
    Title:
    Manager of Supernova Management LLC, the General Partner of Magnetar Capital Partners LP
             
     
    SUPERNOVA MANAGEMENT LLC
     
             
     
    By:
    /s/ David J. Snyderman
     
       
    Name:
    David J. Snyderman
     
       
    Title:
    Manager
     
             
     
    /s/ David J. Snyderman
       
     
    David J. Snyderman
       


    SCHEDULE B
    Funds
     
    Date
    Number of Shares Sold
    Price Per Share($) (1)(2)
    9/30/2022
    166
    31.69343 (3)
    10/3/2022
    634
    31.93684(4)
    10/4/2022
    634
    32.40144(5)
    10/5/2022
    627
     32.05453(6)
    10/6/2022
    637
    31.91645(7)
    10/7/2022
    638
    31.82821(8)


    (1)
    Excludes commissions and other execution-related costs.
     

    (2)
    Upon request by the staff of the Securities and Exchange Commission, full information regarding the number of shares bought or sold (as the case may be) at each separate price will be provided.
     

    (3)
    Reflects a weighted average purchase price of $31.69343 per share, at prices ranging from $31.53 to $31.91 per share.
     

    (4)
    Reflects a weighted average purchase price of $31.93684 per share, at prices ranging from $31.74 to $32.04 per share.
     

    (5)
    Reflects a weighted average purchase price of $32.40144 per share, at prices ranging from $32.20 to $32.53 per share.
     

    (6)
    Reflects a weighted average purchase price of $32.05453 per share, at prices ranging from $31.93 to $32.28 per share.
     

    (7)
    Reflects a weighted average purchase price of $31.91645 per share, at prices ranging from $31.84 to $31.95 per share.
     

    (8)
    Reflects a weighted average purchase price of $31.82821 per share, at prices ranging from $31.78 to $31.87 per share.

    Date
    Number of Shares Bought
    Price Per Share($) (1)(2)
    11/01/22
    15,699
    32.00742 (9)
     

    (9)
    Reflects a weighted average purchase price of $32.00742 per share, at prices ranging from $31.99 to $32.04 per share.


    EXHIBIT INDEX

    Exhibit No.
     
    Description

     
         
    99.2
     
    Joint Filing Agreement, dated as of November 2, 2022, among the Reporting Persons.



    Get the next $VIVO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VIVO

    DatePrice TargetRatingAnalyst
    2/7/2022$28.00 → $30.00Buy
    HC Wainwright & Co.
    11/15/2021$27.00 → $28.00Buy
    HC Wainwright & Co.
    8/9/2021$30.00 → $27.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $VIVO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SD Biosensor and SJL Partners Complete Transaction to Acquire Meridian Bioscience

      CINCINNATI and SEOUL, South Korea, Jan. 31, 2023 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, and SD Biosensor, Inc. ("SDB") (KOSE: A137310) and SJL Partners LLC ("SJL") (collectively, the "Consortium"), announced today that they have completed the transaction to acquire Meridian. Under the terms of the merger, Meridian shareholders have the right to receive $34.00 per share in cash. Meridian stock will no longer be traded on the NASDAQ Global Select Market. Meridian will cont

      1/31/23 1:56:00 PM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • DoubleVerify Holdings to Join S&P SmallCap 600

      NEW YORK, Jan. 25, 2023 /PRNewswire/ -- DoubleVerify Holdings Inc. (NYSE:DV) will replace Meridian Bioscience Inc. (NASD: VIVO) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, January 31. SD Biosensor is acquiring Meridian Bioscience in a deal expected to be completed soon pending final conditions. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector January 31, 2023 S&P SmallCap 600 Addition DoubleVerify Holdings DV Inf

      1/25/23 5:58:00 PM ET
      $DV
      $SPGI
      $VIVO
      Computer Software: Programming Data Processing
      Technology
      Finance: Consumer Services
      Finance
    • Meridian Bioscience Announces Anticipated Closing Date of the Pending Merger

      CINCINNATI, Dec. 12, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced that it has entered into a side letter with the buyer, setting the closing date of Meridian's pending merger for January 31, 2023. As previously disclosed, on July 7, 2022, Meridian, entered into an Agreement and Plan of Merger (the "Merger Agreement") with SD Biosensor, Inc., ("SDB"), Columbus Holding Company ("Parent"), and Madeira Acquisition Corp., a direct wholly owned subsidiary of Parent ("

      12/12/22 8:00:00 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VIVO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • December 10, 2021 - Coronavirus (COVID-19) Update: December 10, 2021

      For Immediate Release: December 10, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On December 9, 2021, the FDA updated the SARS-CoV-2 Viral Mutations: Impact on COVID-19 Tests web page to share the latest information. The update added new information about the Meridian Bioscience, Inc. Revogene SARS-CoV-2 test, inc

      12/10/21 1:56:40 PM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VIVO
    SEC Filings

    See more
    • SEC Form 15-12G filed by Meridian Bioscience Inc.

      15-12G - MERIDIAN BIOSCIENCE INC (0000794172) (Filer)

      2/13/23 4:31:51 PM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 10-Q filed by Meridian Bioscience Inc.

      10-Q - MERIDIAN BIOSCIENCE INC (0000794172) (Filer)

      2/9/23 8:23:24 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form EFFECT filed by Meridian Bioscience Inc.

      EFFECT - MERIDIAN BIOSCIENCE INC (0000794172) (Filer)

      2/6/23 12:15:16 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VIVO
    Financials

    Live finance-specific insights

    See more
    • Meridian Bioscience, Inc. Enters into Agreement to Be Acquired by SD Biosensor and SJL Partners in $1.53 Billion All-Cash Transaction

      Shareholders to Receive $34.00 Per Share in Cash, Providing Immediate, Compelling and Certain Value Transaction Follows Deliberate Review, Including Outreach to Potential Strategic and Financial Partners CINCINNATI and SEOUL, South Korea, July 7, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. ("Meridian" or the "Company") (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, and SD Biosensor, Inc. ("SDB") (KOSE: A137310) and SJL Partners LLC ("SJL") (collectively, the "Consortium") announced today that they have entered into a definitive merger agreement whereby a newly formed affiliate vehicle of the Consortium will acquire Meridian in an a

      7/7/22 7:17:00 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • MERIDIAN BIOSCIENCE REPORTS RECORD SECOND QUARTER FISCAL 2022 OPERATING RESULTS

      CINCINNATI, May 6, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced financial results for the second quarter ended March 31, 2022. Second Quarter Fiscal 2022 Highlights (Comparison to Second Quarter Fiscal 2021): Consolidated net revenues totaled $111.2 million, the highest in Company history, with both segments ahead of expectationsLife Science segment delivered record net revenues of $70.1 millionDiagnostics segment net revenues increased 29% year-over-year to a record $41.1 millionLaunched Lyo-Ready™ sample specific master mixes for bloodResumed

      5/6/22 8:00:00 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Meridian Acquires EUPROTEIN to Further Expand Recombinant Protein Capabilities

      CINCINNATI, Ohio, May 2, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has acquired, through its subsidiary Meridian Life Science, Inc., substantially all of the assets of EUPROTEIN Inc.  The transaction closed on April 30, 2022. EUPROTEIN Inc. offers custom development and production of high-quality bioresearch reagents, with a particular focus on human and other mammalian proteins and recombinant monoclonal antibodies.  This acquisition will help

      5/2/22 8:47:00 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VIVO
    Leadership Updates

    Live Leadership Updates

    See more

    $VIVO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $VIVO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Meridian Bioscience Announces Retirement of CFO Bryan Baldasare

      CINCINNATI, Dec. 2, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that Bryan Baldasare, Executive Vice President, Chief Financial Officer, and Secretary, will retire from Meridian effective December 31, 2021.  The Company is engaging an executive search firm in the recruitment of a new chief financial officer.  The Company appointed Julie Smith to the position of Senior Vice President, Controller, effective December 6, 2021, and principal accounting officer, effective January 1, 2022.

      12/2/21 8:00:00 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Meridian Bioscience Announces Retirement of Chairman David Phillips

      CINCINNATI, Nov. 24, 2021 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that David Phillips, Chairman of the Board of Directors, will retire from the Board of Directors and not seek re-election when his term ends in January 2022.  The Board of Directors will elect a new chair when Mr. Phillips' term expires and will not replace the vacated seat, which will reduce the number of directors to eight. Mr. Phillips joined the Meridian Board of Directors in 2000 and ha

      11/24/21 9:05:00 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Meridian Bioscience Inc. (Amendment)

      SC 13G/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)

      2/9/23 11:27:43 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13D/A filed by Meridian Bioscience Inc. (Amendment)

      SC 13D/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)

      2/3/23 2:06:19 PM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Meridian Bioscience Inc. (Amendment)

      SC 13G/A - MERIDIAN BIOSCIENCE INC (0000794172) (Subject)

      1/31/23 11:06:04 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4: Williams Felicia returned 10,274 shares to the company, closing all direct ownership in the company

      4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)

      1/31/23 2:22:23 PM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4: Sazdanoff Catherine returned 16,424 shares to the company, closing all direct ownership in the company

      4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)

      1/31/23 2:21:33 PM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4: Rice John Mccune Jr. returned 27,449 shares to the company, closing all direct ownership in the company

      4 - MERIDIAN BIOSCIENCE INC (0000794172) (Issuer)

      1/31/23 2:20:26 PM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $VIVO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Meridian Bioscience with a new price target

      HC Wainwright & Co. reiterated coverage of Meridian Bioscience with a rating of Buy and set a new price target of $30.00 from $28.00 previously

      2/7/22 6:13:53 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • HC Wainwright & Co. reiterated coverage on Meridian Bioscience with a new price target

      HC Wainwright & Co. reiterated coverage of Meridian Bioscience with a rating of Buy and set a new price target of $28.00 from $27.00 previously

      11/15/21 6:32:31 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • HC Wainwright & Co. reiterated coverage on Meridian Bioscience with a new price target

      HC Wainwright & Co. reiterated coverage of Meridian Bioscience with a rating of Buy and set a new price target of $27.00 from $30.00 previously

      8/9/21 6:33:26 AM ET
      $VIVO
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care